Sustained Collaboration Meets Needs for Bladder Exstrophy

Share this content:
Sustained Collaboration Meets Needs for Bladder Exstrophy
Sustained Collaboration Meets Needs for Bladder Exstrophy

FRIDAY, March 9, 2018 (HealthDay News) -- International collaboration focused on treating bladder exstrophy-epispadias complex (BE) and penopubic epispadias (PE) in India is associated with acceptable outcomes, according to a study published online March 7 in JAMA Surgery.

Rakesh S. Joshi, M.D., from the B.J. Medical College and Civil Hospital in Ahmedabad, India, and colleagues examined whether a collaboration predicated on long-term commitment by surgeons returning to the same institution annually combined with an experienced host surgical team and infrastructure could provide surgical care with acceptable outcomes in a study conducted in Ahmedabad, India, between January 2009 and January 2015. Comprehensive examination, measurement of continence outcomes, and assessment of surgical complications were conducted during recall of the postoperative cohort in January 2016. Fifty-seven patients who underwent complete primary repair of exstrophy returned for annual follow-up and made up the study cohort (23 with primary BE; 19 with redo BE, and 11 with PE repair).

The researchers found that all BE and three PE repairs (27 percent) were completed with concurrent anterior pubic osteotomies. Thirty-two percent of the patients experienced complications; only one patient with BE (4 percent) had bladder dehiscence and underwent repair the following year.

"A unique surgical mission model consisting of an international collaborative focused on treating the complex diagnoses of BE and PE offers outcomes comparable with those in high-income countries," the authors write. "Postoperative care following a systematized algorithm and rigorous follow-up is mandatory to ensure safety and optimal outcomes."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »